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Abstract: 
Purpose: We hypothesized that patients with sepsis and AKI, especially patients without preserved 
renal function, and treated with continuous veno-venous hemodiafiltration (CVVHDF) have lower 
risk for mortality than patients treated with continuous veno-venous hemofiltration (CVVH).  
Materials and Methods: Patients were included if they fulfilled the diagnosis of severe sepsis or 
septic shock, suffered AKI and received continuous renal replacement therapy (CRRT) in intensive 
care unit. There were 62 patients treated by CVVH and 75 treated by CVVHDF.  
Results: Mean survival time was longer in CVVHDF group with oliguric/anuric patients than in 
CVVH group. CVVH and not classic risk factors was associated with higher overall mortality in 
oliguric/anuric patients.  In the linear regression model hourly urine output was the strongest and 
positive predictor of longer survival. 
Conclusions: CVVHDF is according to our results a CRRT modality of choice for the treatment 
and lower mortality of septic patients with AKI where renal function is no longer preserved. CRRT 
has been associated with improved renal recovery, but it should be started earlier in AKI evolution 
with still preserved hourly urine output which is the most sensitive and prognostic marker of 
survival in septic patients with AKI.  
 
 
 
 
 
 
 
 
 
 
Introduction: 
  Sepsis is a serious medical condition characterized by a whole-body inflammatory state (systemic 
inflammatory-response syndrome, SIRS) and the presence of a known or suspected infection that 
has severe consequences, including multiple organ failure (MOF). The clinical diagnosis of sepsis 
requires finding a focus of infection as well as at least two signs of SIRS that comprise abnormal 
body temperature (higher than 38°C or less than 36°C), heart rate >90 beats/min, respiration >20 
breaths/min or arterial partial pressure of CO2 <32 mmHg, and deranged white blood cell counts 
(greater than 12 x 10
3/
mm
3
, less than 4 x 10
3
/mm
3
, or greater than 10% immature bands [1]. The 
progress of sepsis in severe sepsis is characterized by failure of organ systems and can be  identified 
as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥2 points 
consequent to the infection. Septic shock is a subset of sepsis in which underlying circulatory and 
cellular/metabolic abnormalities are profound. Patients with septic shock can be identified with a 
clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain mean 
arterial pressure (MAP)≥65 mmHg and having a serum lactate level >2 mmol/L despite adequate 
volume resuscitation [2,3]. 
Acute kidney injury (AKI) is a frequent and serious complication of sepsis in intensive care unit 
(ICU) patients, in all age groups [4]. Moreover, there is strong evidence that sepsis and septic shock 
are the most important causes of AKI in critically ill patients, account for 50% or more of cases of 
AKI in ICUs, and associate with a very high mortality [5,6]. 
The pathophysiology of AKI in sepsis is complex and multi-factorial and includes intrarenal 
hemodynamic changes, endothelial dysfunction, infiltration of inflammatory cells in the renal 
parenchyma, intraglomerular thrombosis, and obstruction of tubules with necrotic cells and debris 
[5]. A growing body of evidence now suggests that the sepsis-induced immune responses involve 
the activation, in a sequential manner, of both pro- and anti-inflammatory mechanisms [7]. 
Some studies suggest that continuous renal replacement therapy (CRRT) is associated with 
increased ability to clear inflammatory mediators [5,6] from septic patients with AKI. There are two 
methods of clearance in continuous veno-venous hemodiafiltration (CVVHDF), diffusion and 
convection, while only convection in continuous veno-venous hemofiltration (CVVH). Convective 
modalities (hemofiltration) may provide better clearance of middle molecular weight solutes like 
cytokines compared with diffusive modalities [7]. Nevertheless, there are only few studies 
examining the impact of different CRRT modalities, especially CVVH and CVVHDF on survival in 
septic patients with AKI.   
As sepsis associated with AKI has an increased short-term mortality and increased circulating 
cytokines mediates the development of septic shock and sepsis-associated AKI, we hypothesized 
that patients with sepsis and AKI and treated with CVVHDF have lower risk for mortality than 
other patients treated with CVVH. Additionaly, because there are no present data on possible 
differences in survival of oligoanuric and non-oliguric septic patients with AKI, we hypothesized 
that CVVHDF, a combination of two methods, is a CRRT modality of choice for the treatment and 
lower mortality of septic patients with AKI where renal function is no longer preserved. To test this 
hypotheses we analyzed clinical course of the patients through the hospitalization and survival rate 
after follow-up.  
 
 
 
 
 
 
 
 
 
Materials and Methods: 
This was a retrospective, longitudinal follow-up study for 12 months duration. In total, 137 patients 
were recruited from the ICUs in University Hospital Center Zagreb, Croatia.  
Patients were included if they fulfilled the diagnosis of severe sepsis or septic shock, suffered AKI 
and received CRRT in ICU. Sepsis was defined as the presence of suspected or documented 
infection together with systemic inflammatory response syndrome while septic shock was defined 
as a status of sepsis with acute circulatory failure according to the American College of Chest 
Physicians/ Society of Critical Care Medicine/European Society of Intensive Care Medicine criteria 
[1]. Other inclusion criteria included renal dysfunction (defined on the basis of an estimated 
creatinine clearance - eGFR, mL/min was calculated daily using the simplified Modification of Diet 
in Renal Disease (MDRD) equation [8]. Acute kidney injury was defined by a modified definition 
of the Kidney Disease: Improving Global Outcomes (KDIGO) AKI Workgroup, harmonizing 
differences between the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease 
(RIFLE) and the Acute Kidney Injury Network (AKIN) definitions [9]. Those with age less than 18 
years old, presence of chronic kidney disease stage 5 (GFR<15mL/min per 1.73/m
2
), end stage 
renal failure on long term dialysis or those treated with RRT before ICU admission were excluded.  
Hourly fluid input and urine output data were extracted from ICU charts. At admission and after 
each treatment documented body weight was used. Patient follow- up continued until the last 
enrolled patient reached the 365-day time point. Each patient underwent a complete clinical and 
laboratory examination at the time of admission and during hospitalization. Selection of CVVH and 
CVVHDF as the primary treatment method was the choice of the involved nephrologist. Generally, 
patients with lower eGFR levels and a need of diffusion for reduction of serum creatinine and blood 
urea nitrogen (BUN) or potassium levels were referred for CVVHDF. Both modalities, CVVH and 
CVVHDF were performed for each patient using the Prismaflex® CRRT and M100 membrane 
filters (Baxter Int., Deerfield, Illinois, USA). The patients have been  followed by telemetry unit. A 
patient to nurse ratio was 2:1. Forty-five percent of patients were treated with CVVH and 55% with 
CVVHDF. Data for each patient concerning UF rates, duration of each treatment, blood, dialysate 
and replacement fluid pump flows and total number of treatments were obtained. Blood flow rate 
was maintained at between 200 mL/min and 250 mL/min, according to blood-access function and 
desired UF rates. Anti-coagulation was performed according to patient condition, either with low 
molecular weight heparin or heparin-free anti-coagulation. The hemofilter and the extracorporeal 
circuit were replaced every 72 hours. Ultrafiltration rates were prescribed depending on patients 
cardiac status, fluid overload and hourly urine output. The rates of reinfusion and dialysate were 
prescribed aiming at the dose of dialysis >35 ml/kg/hour.   
Discontinuation of treatment and discharge has been done by the treating intensive care physician 
(after consultation with nephrologist), based on clinically assessed volume status, symptoms, and 
objective data (including laboratory values). Plasma creatinine, blood urea nitrogen (BUN), serum 
sodium and potassium, C-reactive protein, serum albumin and white cell blood count were analyzed 
from blood samples at start and at the end of each treatment. Systolic and diastolic blood pressure 
were measured before, during and after each treatment (and in the meantime, as it was indicated). A 
direct measurement of volume overload has been performed using central venous catheter (CVP, 
expressed in mmHg).  
Ethical approval: All subjects enrolled in this research have given their informed consent, which has 
been approved by my institutional committee on human research, and this protocol has been found 
acceptable by them.  
Statistical analysis was performed using SPSS version 23.0 (IBM Corp., USA). Normality of data 
distribution was tested using Kolmogorov-Smirnov test. Preliminary analyses were performed to 
ensure no violation of the assumptions of normality, linearity and homoscedasticity. Descriptive 
characteristics were expressed as numbers and frequencies. Correlations were obtained using 
Pearson's test for normally distributed variables and Spearman rank correlation for non-normally 
distributed variables. Normally distributed variables were presented as means + standard deviations 
and Student’s t test for independent samples was used for comparisons between two groups. Non-
normally distributed data was presented as median and interquartile range and Mann-Whitney U-
test was used in comparison between two groups. Baseline-to-Follow-up comparisons were done 
using Student's t-test for paired samples and Wilcoxon test. Categorical variables were compared 
using χ2- test. Survival analysis was done with Kaplan-Meier curves which were tested with log-
rank test while hazard ratios were estimated with Cox proportional hazards regression. Multiple 
linear regression was used to explore the influence of different variables on survival, while logistic 
regression was used for categorical dependent variables. We constructed three regression models to 
assess independent associations of multiple independent variables with patients survival. In Model 1 
we included variables known to be associated with increased mortality and related to dialysis: age, 
body weight at baseline and the end of treatment, duration of dialysis, hourly urine output, sex and 
presence of diabetes and hypertension (yes/no). Model 2 included, in addition to all variables in 
Model 1 those further related to the dialysis: serum creatinine, BUN, ultrafiltration rate and central 
venous pressureat baseline and end of the treatment. Model 3 was additionally adjusted for 
established laboratory parameters of sepsis and chronic disease: c-reactive protein and serum 
albumins.  A p value <0.05 (two-sided tests) was considered significant. 
 
 
 
 
 
 
 
 
 
 
 
Results:  
There were 62 patients treated by CVVH (37 /59.6%/ males) and 75 CVVHDF treated patients (42 
/56.0%/ males) at the beginning of the study. The follow-up completed 44 CVVH treated patients 
and 45 CVVHDF treated patients. Demographic, laboratory and clinical characteristics of patients 
treated with CVVH and CVVHDF at start and end of treatments are demonstrated in Table 1. There 
were no differences in age and gender between CVVH and CVVHDF groups and with no 
differences in percentage of arterial hypertension or diabetes. No significant differences were 
observed in body weight, duration of hospitalization and number of dialysis treatments both at start 
and end of treatments. Patients treated with CVVH had bigger reinfusion and ultrafiltration rates 
(UFR) than CVVHDF patients (p<0.05). The standard dialysate flow rate for patients treated with 
CVVHDF was 1309 ml/h. The initialization of treatments was at significantly higher values of 
serume creatinine and BUN in CVVHDF patients while there was no difference in hourly urine 
output between two groups of patients. As shown in Table 1. at start and at the end of treatments 
there were no differences in brachial BP values and CVP values as well as in laboratory markers of 
sepsis, CRP, WBC and albumins. There was no difference in survival between two groups of 
patients. When patients were divided by hourly urine output on oliguric/anuric and non-oliguric we 
have not find any significant differences between two groups of patients except longer survival in 
non-oliguric group. On univariate analysis survival was in all patients negatively correlated with 
age (r=-0.329; p<0.001), duration of dialysis (r=-0.193; p=0.024) and serum creatinine (r=-0.209; 
p=0.014) at the end of treatments and positively with hourly urine output (r=0.573; p<0.001) and 
serum albumins (r=0.172; p=0.044). In oliguric/anuric patients we have not find any significant 
correlations between survival and other variables. In all three linear regression models hourly urine 
output was the strongest and positive predictor of longer survival (β= 0.492, β= 0.496 and β= 0.492, 
all p<0.001). Additionally, in Model 1 (adjusted R
2=0.395) age (β=-0.282, p<0.001) and duration of 
dialysis (β=-0.188, p=0.007) showed negative association with survival. In Model 2 (adjusted 
R
2=0.413) age (β=-0.266, p<0.001) and duration of dialysis (β=-0.217, p=0.003) were negatively 
associated with survival. Model 3 (adjusted R
2
=0.403) showed negative significant associations of 
survival with age (β=-0.266, p<0.001) and duration of dialysis (β=.0.216, p=0.004). The patients 
were followed for 12 months, 21 CVVH and 27 CVVHDF patients survived. Thirty-one patients 
have died from multi-organ failure caused by sepsis and ten patients have died from heart failure in 
the CVVH group while thirty-three patients have died from multi-organ failure caused by sepsis and 
15 patients have died from heart failure in the CVVHDF group of patients. There was no difference 
in mean survival time between CVVH and CVVHDF patients (280.1 (95% CI 249.9, 311.6) vs. 
274.7 (95% CI 239.9, 310.6) days) (Figure 1). Demographic, laboratory and clinical characteristics 
of oliguric/anuric patients with treated with CVVH and CVVHDF are demonstrated in Table 3. 
There were no differences in age, gender and percentage of arterial hypertension and diabetes 
between CVVH and CVVHDF groups. There were no differences in dialysis parameters between 
two groups. The initialization of treatments were at significantly higher values of serume creatinine 
in CVVHDF patients (p=0.03). Mean survival time was longer in CVVHDF group with 
oliguric/anuric patients than in CVVH group (110.4 (95% CI 53.8, 167.1) vs. 22.9 (95% CI 0.9, 
51.2) days, log-rank p=0.006) (Figure 2). All non-oliguric patients had a significantly longer 
survival time compared to oliguric/anuric patients group (229.5 (95% CI 199.9, 259.1) vs. 74.2 
(95% CI 36.7, 111.6) days, log-rank p<0.001). Non-oliguric patients treated with CVVH had 
significant longer survival than oliguric/anuric patients as well as patients treated with CVVHDF 
modality (both log-rank p<0.001). CVVH (HR 2.06 [0.98, 4.32]) and not classic risk factors as age, 
dialysis parameters and inflammatory marker levels was associated with higher overall mortality in 
oliguric/anuric patients while in all group of patients only age (HR 1.04 [1.02, 1.06]) was associated 
with higher overall mortality. We have not find significant differences in survival time in non-
oliguric patients treated with CVVH and CVVHDF (Figure 3.) as well when patients were divided 
by different dose of dialysis and hourly urine output. There were no differences in renal survival 
between CVVH and CVVHDF in survived patients. Renal outcome transitioned to chronic 
hemodialysis in four patients in CVVH group and three patients in CVVHDF group. 
Discussion: 
  Sepsis and septic shock remain the most important cause of AKI in critically ill patients and septic-
associated AKI. They account for approximately 50% of cases of AKI in the ICU [10-12], 
complicate between 15% and 20% of all ICU admissions with severe septic-associated AKI, and are 
responsible for triggering renal replacement therapy in 2% to 3% of all ICU admission [13,14]. 
Mortality in patients with sepsis and AKI is still very high (between 40 and 55%), as it was 
demonstrated by two recent large studies [15,16]. When compared with AKI of nonseptic origin, 
septic AKI patients have a significantly and unacceptably high mortality [17]. Unlike to previous 
reviews, AKI is a relatively common cause of long-term mortality and development of chronic renal 
failure (including end-stage renal failure, ESRD). There are only few present data comparing 
different CRRT modalities, namely CVVH and CVVHDF for treatment of septic patients with 
associated AKI. 
     In this study we did not found significant difference in survival between septic patients with 
associated AKI treated with CVVH and CVVHDF at the end of the follow-up period (Figure 1.). To 
our knowledge this is in agreement with only one present study [18]. Although patients treated with 
CVVH had higher reinfusion and UF rates than CVVHDF patients, treatments were initiated at 
significantly higher values of serume creatinine and BUN in CVVHDF patients with no difference 
in hourly urine output between two groups of patients (Table 1.). Treatment was initiated at similar 
levels of sepsis parameters in both groups of patients. Patients treated with CVVHDF had a 
significant decrease in serum creatinine and BUN levels at the end of the follow-up compared to 
CVVH patients as a sign of combination of two basic principles of dialysis, convection and 
diffusion. 
      Hourly urine output is a sensitive and specific biomarker that provides an early warning signal 
for AKI and higher mortality [19,20]. The hourly urine output in our study was a significant and 
independant predictor of longer survival in all patients with the same association present when they 
were divided by hourly urine output in non-oliguric subgroup. Regarding to our results, serum 
creatinine and BUN were not a significant predictors of better survival. When divided only by 
hourly urine output, patients with urine output <10 ml/h did not survived longer compared to 
patients with urine output >10 ml/h.  
Although CRRT removes pro- and anti-inflammatory cytokines, outcomes do not seem to be 
affected regardless of the dose applied [21,22] which was the same as the results in our study. 
When divided on subgroups by hourly urine output and different CRRT modality, significantly 
higher number of patients with oliguria/anuria treated with CVVHDF survived compared to patients 
treated with CVVH (Figure 2). Interestingly, there was no difference in survival in non-oliguric 
patients treated with different CRRT modalities (Figure 3). 
Sepsis is characterized by release of excessive amounts of proinflammatory cytokines in the 
circulation which could be downregulated with the CRRT by nonspecific extracorporeal removal of 
cytokines and other mediators [21-23]. Some studies indicate that cytokine removal with current 
CRRT methods and synthetic membranes is more convective than diffusive [24,25] which is in 
contrast to our findings. The results from Graziani et al. [26] suggested that in septic patients with 
preserved diuresis some pro-inflammatory cytokines were removed from the plasma and non-
oliguric patients had a better prognosis than oliguric/anuric patients. No difference in survival 
between non-oliguric septic patients treated with CVVH and CVVHDF could be observed through 
the cytokine removal from the plasma due to still preserved diuresis while in the other group of 
patients, kidneys lost the function of cytokine removal. It is possible that cytokine accumulation 
was better controled with the combination of convection and diffusion, which is in contrast to 
previous results, especially when taking into account the fact that the improvement of eGFR and 
therefore renal function was more pronounced in CVVHDF patients. Furthermore, CVVH and not 
CVVHDF was associated with higher overall mortality in oliguric/anuric patients. However, this 
hypothesis needs further investigations. 
When we compared patients with different hourly urine output, all oliguric/anuric patients and those 
treated with different CRRT methods survived significantly shorter compared to non-oliguric 
patients. This is an additional argument for our hypothesis of cytokine removal by still preserved 
renal hourly urine output in septic patients with AKI. 
This is the first study which analyzed the impact of different CRRT modalities (CVVH vs. 
CVVHDF) and hourly urine output on survival of septic patients with AKI. Our results on better 
survival of septic  oliguric/anuric patients treated with CVVHDF are in line with our hypothesis that 
CVVHDF, a combination of two methods, is a CRRT modality of choice for the treatment and 
lower mortality of septic patients with AKI where renal function is no longer preserved. The present 
study suggests that the use of CVVHDF in septic non-oliguric patients is not associated with 
improved survival when compared with CVVH. Furthermore, the cytokine reduction in septic 
patients could not be only achieved by CRRT especially when renal function is still preserved and 
kidneys have the ability of cytokine removal from plasma. Based on our results, hourly urine output 
is the most sensitive and prognostic marker of survival in septic patients with AKI. 
 
Our work has several limitations. First, the study was an observational, non-randomised performed 
in a single centre and it could be limited by a relatively small sample size. Second, cytokine levels 
were not measured in this study. Plasma levels of TNF alfa, IL-1b, IL-6 and IL-8, related to pro-
inflammatory state have a greater accuracy than clinical signs for the diagnosis of sepsis. The effect 
of cytokine removal by CVVHDF especially in oliguric/anuric patients could not be assesed 
directly but only by clinical signs and better survival compared to patients treated with CVVH. 
Third, all the included patients already had a presence of AKI. Some could argue why we did not 
include patients treated with CVVHD and therefore analyzed the impact on survival of three 
different CRRT modalities. In patients with AKI and a clinical signs of sepsis, convection, and not 
diffusion has been considered a method of choice [27,28] and we wanted to analyze only the 
addition of diffusion to convection. Furthermore, most patients treated with CVVHD had a presence 
of previous chronic kidney disease so they were not eligible for this study. Fourth, patient selection 
bias may play a role in choosing the dialysis mode in which patients with higher serum creatinine 
levels received CVVHDF.  
Conclusion: The identification of high-risk patients is crucial in influencing outcome of the patients 
with sepsis-induced AKI. CVVHDF, a combination of two methods, is according to our results a 
CRRT modality of choice for the treatment and lower mortality of septic patients with AKI where 
renal function is no longer preserved. Although rare, nospecific treatments for septic AKI, early 
antibiotic administration, avoidance of hypotension (through fluid administration or vasopressors), 
nephrotoxic agents and fluid overload can minimize AKI risk. Continuous renal replacement 
therapy, based on our results, should be started earlier in AKI evolution with still preserved hourly 
urine output which is the most sensitive and prognostic marker of survival in septic patients with 
AKI. Future trials should be designed to identify high-risk patients with early injury and focus on 
targeted therapy.  
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Table 1. Demographic, clinical and laboratory data of enrolled patients 
 
 CVVH CVVHDF p 
No. of patients 62 75  
Age (years) 62.5 (42.8-81.4) 62.9 (42.6-82.2) 0.87 
Sex (male) N (%) 37 (59.6%) 42 (56.0%) 0.57 
Body weight (kg) 
baseline 
81.5+10.5 80.5+10.4 0.57 
Body weight (kg) end of 
treatments 
80 (55-116) 79 (54-112) 0.48 
Duration of 
hospitalisation (days) 
32.8 (7.4-58.6) 34.5 (8.2-59.8) 0.64 
Hypertension (Yes) N 
(%) 
42 (67.7%) 49 (65.3%) 0.34 
Diabetes (Yes) N (%) 18 (29.0%) 20 (26.6%) 0.31 
Duration of dialysis 
(hours) 
18 (12-25) 17 (11-23) 0.45 
Blood pump flow (ml/h) 216 (158-278) 222 (164-286) 0.29 
Reinfusion pump flow 
(ml/h) 
1887 (1324-2292) 1281 (892-1706) <0.001 
UFR (ml/hour) 149 (130-161) 124 (102-148) 0.01 
Total days of dialysis 15.7 (12.0-19.2) 17.4 (13.1-21.3) 0.59 
eGFR (ml/min) baseline 21.0 (14.8-27.2) 15.2 (10.6-19.8) <0.001 
Serum creatinine 
(umol/L) baseline 
284 (226-352) 388 (320-456) <0.001 
eGFR (ml/min) end of 
treatments 
29.1 (23.3-35.4) 32.4 (26.8-38.1) 0.36 
Serum creatinine 
(umol/L) end of 
treatments 
211 (154-273) 197 (135-260) 0.43 
BUN (nmol/L) baseline 25.8 (21.6-32.0) 27.8 (23.2-33.6) 0.30 
BUN (nmol/L) end of 
treatments+ 
19.9+2.1 15.1+2.9 0.04 
Sodium (mmol/L) 
baseline 
135 (127-144) 135 (125-143) 0.95 
Sodium (mmol/L) end of 
treatments 
135 (126-143) 134 (123-144) 0.23 
Potassium (mmol/L) 
baseline 
4.3 (3.9-4.8) 4.4 (3.9-4.8) <0.001 
Potassium (mmol/L) end 
of treatments 
4.0 (3.6-4.5) 4.1 (3.6-4.6) 0.05 
C-reactive protein 
(mg/L) 
173.3 (102.6-258.4) 173.2 (104.2-254.6) 0.99 
WBC (x10
9
/L) 16.3 (12.4-20.8) 16.9 (12.8-21.2) 0.62 
Serum albumin (g/L) 39.1 (26.8-52.6) 39.4 (26.2-52.9) 0.86 
Systolic blood pressure 
(mmHg) baseline 
133 (112-154) 132 (110-152) 0.34 
Systolic blood pressure 
(mmHg) end of 
treatments 
121 (104-138) 122 (106-140) 0.55 
Diastolic blood pressure 
(mmHg) baseline 
84 (70-94) 84 (72-96) 0.58 
Diastolic blood pressure 
(mmHg) end of 
treatments 
72 (64-82) 72 (62-81) 0.78 
Central venous pressure 
(mmHg) baseline+ 
21 (5-30) 20 (4-28) 0.18 
Central venous pressure 
(mmHg) end of 
treatments 
14.5+3.4 14.1+3.2 0.52 
Hourly urine output 
(ml/hour)  
10.3+0.4 9.5+0.5 0.22 
Survival (days) 189 (120-258) 177 (102-256) 0.64 
CVVH-continuous veno-venous hemofiltration; CVVHDF-continuous veno-venous hemodiafiltration; UFR-
ultrafiltration rate; eGFR-estimated glomerular filtration rate; BUN-blood urea nitrogen; WBC-white blood 
count; results are shown as mean +/- SD or median (interquartile range) 
 
 
 
 
 
Table 2. Linear regression model  
 
 
Coefficientsa     
BetaModel Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig.  
 
1BStd. 
Error 
(Constant) 111,419 146,097  ,763 ,447 
Age -2,862 ,757 -,266 -3,783 ,000 
Body weight baseline 7,877 4,296 ,521 1,833 ,069 
  Body weight end of    
treatments 
-7,827 4,513 -,492 -1,735 ,085 
Duration of dialysis -6,413 2,201 -,216 -2,914 ,004 
Hourly urine output 20,428 2,959 ,492 6,904 ,000 
Sex m=0 ž=1 24,293 24,808 ,071 ,979 ,329 
Hypertension da=0 ne=1 7,892 23,682 ,024 ,333 ,740 
Diabetes da=0 ne=1 37,030 31,366 ,089 1,181 ,240 
Ultrafiltration -,035 ,205 -,013 -,172 ,863 
Creatinine baseline -,033 ,082 -,034 -,397 ,692 
Creatinine end of treatments -,033 ,125 -,022 -,264 ,792 
CVP baseline -,674 3,334 -,022 -,202 ,840 
CVP end of treatments 8,211 4,614 ,194 1,780 ,078 
C-reactive protein ,111 ,141 ,055 ,788 ,432 
Albumins ,771 1,843 ,052 ,418 ,676 
      
a. Dependent Variable: Survival in days     
CVP-central venous pressure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Demographic, clinical and laboratory data in oliguric/anuric patients 
 
 CVVH CVVHDF p 
No. of patients 17 24  
Age (years) 65.7 (44.2-80.1) 63.0 (42.0-79.8) 0.52 
Sex (men) N (%) 7 (41.1%) 10 (41.6%) 0.39 
Body weight (kg) 
baseline 
78.8+10.5 80.8+9.5 0.54 
Body weight (kg) end of 
treatments 
79 (48-106) 78 (46-100) 0.92 
Duration of 
hospitalisation (days) 
26.0 (8.2-47.1) 28.8 (9.4-49.2) 0.60 
Hypertension (Yes) N 
(%) 
6 (35.3%) 10 (41.6%) 0.09 
Diabetes (Yes) N (%) 5 (29.4%) 7 (29.1%) 0.59 
Duration of dialysis 
(hours) 
18.1 (13.4-23.7) 17.7 (12.2-21.8) 0.81 
Blood pump flow (ml/h) 240 (218-272) 227 (201-259) 0.16 
UFR (ml/hour) 165 (142-182) 133 (111-159) 0.12 
Total days of dialysis 13.4 (11.4-15.7) 14.9 (12.8-16.5) 0.77 
eGFR (ml/min) baseline 22.3 (16.1-28.2) 14.2 (8.1-20.3) 0.02 
Serum creatinine 
(umol/L) baseline 
272 (210-341) 394 (331-460) 0.03 
eGFR (ml/min) end of 
treatments 
27.5 (21.2-33.8) 29.5 (23.1-35.8) 0.61 
Serum creatinine 
(umol/L) end of 
treatments 
227 (160-289) 214 (151-279) 0.72 
BUN (nmol/L) baseline 24.2 (20.1-27.9) 25.0 (21.2-29.2) 0.79 
BUN (nmol/L) end of 
treatments 
18.9 (14.1-23.8) 16.0 (12.3-21.8) 0.29 
Sodium (mmol/L) 
baseline 
135 (124-146) 135 (123-147) 0.29 
Sodium (mmol/L) end of 
treatments 
134 (121-144) 134 (120-144) 0.41 
Potassium (mmol/L) 
baseline 
4.3+0.1 4.5+0.1 0.005 
Potassium (mmol/L) end 
of treatments 
4.0+0.1 4.2+0.1 0.05 
C-reactive protein 
(mg/L) 
179.9 (112.2-250.1) 177.7 (110.8-246.6) 0.94 
WBC (x10
9
/L) 17.8 (12.7-23.2) 17.0 (12.2-22.9) 0.15 
Serum albumins (g/L) 38.4 (21.4-54.4) 33.3 (16.3-50.1) 0.68 
Systolic blood pressure 
(mmHg) baseline 
134 (114-152) 130 (108-156) 0.14 
Systolic blood pressure 
(mmHg) end of 
treatments 
124 (105-140) 122 (107-139) 0.53 
Diastolic blood pressure 
(mmHg) baseline 
84 (70-96) 83 (71-94) 0.47 
Diastolic blood pressure 
(mmHg) end of 
treatments 
71 (63-80) 72 (62-82) 0.45 
Central venous pressure 
(mmHg) baseline 
23 (6-31) 20 (4-29) 0.07 
Central venous pressure 
(mmHg) end of 
treatments 
15.1+2.5 13.7+2.2 0.22 
Survival (days) 23 (8-39) 110 (87-138) 0.01 
CVVH-continuous veno-venous hemofiltration; CVVHDF-continuous veno-venous hemodiafiltration; UFR-
ultrafiltration rate; eGFR-estimated glomerular filtration rate; BUN-blood urea nitrogen; WBC-white blood 
count; results are shown as mean +/- SD or median (interquartile range) 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
Outcome for 1-year survival in all patients subdivided by CVVH or CVVHDF treatment at the end of follow-up 
CVVH-continuous veno-venous hemofiltration; CVVHDF-continuous veno-venous hemodiafiltration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. 
 
 
 
 
 
 
Outcome for 1-year survival in oliguric/anuric patients subdivided by CVVH or CVVHDF 
treatment at the end of follow-up 
CVVH-continuous veno-venous hemofiltration; CVVHDF-continuous veno-venous hemodiafiltration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3. 
 
 
 
 
 
 
Outcome for 1-year survival in non-oliguric patients subdivided by CVVH or CVVHDF treatment 
at the end of follow-up 
 
CVVH-continuous veno-venous hemofiltration; CVVHDF-continuous veno-venous hemodiafiltration 
 
